SuPAR in Adult Patients With Covid-19

CompletedOBSERVATIONAL
Enrollment

767

Participants

Timeline

Start Date

October 11, 2020

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Covid19
Interventions
DIAGNOSTIC_TEST

Soluble Urokinase Plasminogen Activator Receptor

Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.

Trial Locations (1)

41110

University Hospital of Larisa, Department of Anesthesiology, Larissa

All Listed Sponsors
lead

University of Thessaly

OTHER

NCT04590794 - SuPAR in Adult Patients With Covid-19 | Biotech Hunter | Biotech Hunter